BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Passes Above 200-Day Moving Average – Time to Sell?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $8.56 and traded as high as $9.48. BioCryst Pharmaceuticals shares last traded at $9.38, with a volume of 1,635,305 shares.

Analysts Set New Price Targets

Several equities analysts have weighed in on BCRX shares. Cantor Fitzgerald lifted their target price on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a research note on Tuesday, June 30th. Wall Street Zen cut shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Royal Bank Of Canada boosted their price objective on shares of BioCryst Pharmaceuticals from $13.00 to $14.00 and gave the company an “outperform” rating in a research report on Tuesday, July 7th. JPMorgan Chase & Co. initiated coverage on shares of BioCryst Pharmaceuticals in a research note on Monday, July 13th. They issued a “neutral” rating and a $12.00 price objective on the stock. Finally, Citizens Jmp increased their target price on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research report on Thursday, May 7th. Eight research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, BioCryst Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $20.80.

BioCryst Pharmaceuticals Trading Down 0.4%

The firm has a 50-day simple moving average of $9.22 and a two-hundred day simple moving average of $8.57. The company has a market capitalization of $2.37 billion, a price-to-earnings ratio of -5.25 and a beta of 0.55.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) EPS for the quarter, missing the consensus estimate of $0.06 by ($3.04). The firm had revenue of $156.41 million during the quarter, compared to the consensus estimate of $151.12 million. BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The company’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.20 EPS. On average, sell-side analysts forecast that BioCryst Pharmaceuticals, Inc. will post -2.58 earnings per share for the current year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. Larson Financial Group LLC increased its position in BioCryst Pharmaceuticals by 1,188.0% during the fourth quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock worth $28,000 after buying an additional 3,267 shares during the last quarter. Focus Partners Wealth acquired a new position in BioCryst Pharmaceuticals during the 3rd quarter valued at $77,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in BioCryst Pharmaceuticals by 26.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 2,115 shares during the period. Envestnet Portfolio Solutions Inc. bought a new stake in BioCryst Pharmaceuticals in the 4th quarter valued at $81,000. Finally, Mercer Global Advisors Inc. ADV acquired a new stake in BioCryst Pharmaceuticals in the 3rd quarter worth $81,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.